<DOC>
	<DOCNO>NCT02344225</DOCNO>
	<brief_summary>Phase 2 , open-label , randomize , multi-center study infant premature infant necessary determine treatment preventative strategy ROP . This study design : ) target infant high risk ROP large number center variable rate ROP ( stage severe ROP stage 3+ ) ; b ) ass whether caffeine plus systemic ophthalmic NSAID decrease ROP among infant risk ROP . The study design determine whether novel treatment regimen safe potentially effective ROP prevention obtain requisite data development Phase III efficacy/safety randomize blinded trial . Since caffeine use extensively NICUs standard care ELGANs , placebo group include .</brief_summary>
	<brief_title>The Synergistic Pharmacologic Intervention Prevention ROP ( SPIPROP Study )</brief_title>
	<detailed_description>This study evaluate safety , tolerability PK-PD , compare contrast , IV Ibuprofen Caffeine Ketorolac eye drop Caffeine ELGAN infants &lt; 28 week GA 14 day duration treat preferably prevent ROP associate prematurity ELGAN . The specific aim trial : Aim 1 : To establish synergistic effect local ophthalmic NSIADs systemic caffeine optimal therapy attenuation and/or prevention severe ROP . Hypothesis : Ocular Ketorolac systemic Ibuprofen potentiate systemic Caffeine prevent diminish severity ROP . We : ) Evaluate safety , tolerability , efficacy early postnatal local ophthalmic NSIADs prevention severe ROP ELGANs . b ) Determine pharmacokinetics , pharmacodymanics pharmacogenomics NSAIDs potentiate caffeine prevention ROP . Aim 2 : To identify `` critical '' number arterial oxygen desaturations key risk factor severe ROP . Hypothesis : A `` critical '' number daily arterial oxygen desaturations first two week life key risk factor severe ROP . We : ) Further define role VEGF , IGF , MMPs , ROS ROP correlate level number arterial oxygen desaturations . b ) Establish identify whether increase serum VEGF infant severe ROP diffusible isoform VEGF121 . This isoform form VEGF proteolysis plasmin MMPs . MMPs also cleave Notch/Dll4 , act regulator VEGF signaling . Aim 3 : To determine whether infant risk severe ROP haploinsufficient delta-like ligand 4 ( Dll4 ) . Hypothesis : ELGANs risk severe ROP different pattern gene expression specifically related Notch signal pathway , previously show animal model . We : ) Examine cord blood , cord tissue , placental tissue compare gene profile VEGF Notch signal pathway among infant develop severe ROP ; b ) Determine whether NSAIDs and/or Caffeine confer protective benefit Notch/Dll4 signal prevent development severe ROP . This phase 2b , randomize , open label , multi-center , safety , tolerability efficacy study compare 3 intervention possible prevention ROP . The trial conduct least 8 investigational site include Neonatal network ( SUNY Downstate Brooklyn-Queens Neonatal Network site , SUNY Stony Brook ) , Miller Children 's Hospital , Long Beach , CA . An independent DSMB ass safety study . This study monitor safety study drug 7 day last dose drug . An exploratory study determine role pharmacodynamic , drug concentration ( surrogate PK profile ) pharmacogenomics also conduct patient population . One hundred twenty preterm infant ( &lt; 28 week gestation ; &lt; 1250 gram ) 0 72 hour life randomize receive either : 1 . Caffeine citrate IV ( 20 mg/kg load dose follow 5 mg/kg/day maintenance dose ) plus placebo saline IV ( 1 ml/kg follow 0.25 ml/kg ) 5 day plus sterile normal saline ( one drop two time day ) 14 day ( n=40 ) ; 2 . Caffeine citrate describe group 1 plus Ibuprofen ( 10 mg/kg load dose follow low dose ibuprofen 2.5 mg/kg/day ) 5 day plus sterile normal saline ( one drop two time day ) 14 day ( n=40 ) ; 3 . Caffeine citrate plus saline IV placebo describe group 1 , Ketorolac ( Acuvail ) eye drop ( one drop two time day ) 14 day ( n=40 )</detailed_description>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Caffeine citrate</mesh_term>
	<criteria>Neonates high risk ROP outline American Academy Pediatrics , Section Ophthalmology ; American Association Pediatric Ophthalmology Strabismus ; American Academy Ophthalmology ( 129 ) enrol . Inclusion criterion : 1. infant birth weight less 1250 gram ; 2. infant gestational age 28 week less ; 3. infant require oxygen therapy ventilator support within first 2 day life . Exclusion criterion : 1. major congenital malformation chromosomal anomaly include ductdependent cardiac anomaly ; 2. maternal antenatal NSAID exposure &lt; 72 hour birth ; 3. renal failure oliguria define urine flow rate &lt; 0.5 mL/kg/hour 8 hour prior randomization . Anuria acceptable infant le 24 hour life ; 4. platelet count &lt; 75,000.mm3 ; 5. clinical bleed oozing puncture sit ; 6. participation clinical drug trial subject participates study 7 day last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Weeks</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>